#bone loss

Rates of HIV acquisition were very low among people taking Descovy or Truvada, but Descovy had less effect on kidneys and bones.

Investigators conducted a review of 20 studies covering 55 health outcomes, looking for those associated with HIV.

HIV-positive individuals tend to develop frailty at a younger age than the general population.

The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.

HIV-positive individuals tend to develop frailty at a younger age than the general population.

Two men claim they developed bone and kidney problems after taking TDF. A related class action lawsuit has also been filed.

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

Those who start antiretroviral (ARV) treatment for HIV soon after diagnosis experience a greater decline in bone mineral density.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Although more research on antiretroviral linked bone loss is needed, the overall health benefits of early treatment outweigh such a risk.

For people living with HIV, exposure to hepatitis C virus (HCV) is linked to a higher risk of kidney disease and bone disorders.

This is according to a study of French men who have well-controlled HIV thanks to antiretroviral treatment.

Also, among those with both viruses, a failed hep C cure attempt is associated with a lower risk of diabetes compared with a successful one.

After losing bone density during a year on PrEP, young men recouped their losses a year later but didn’t catch up with norms.

A single infusion of the osteoporosis drug zoledronic acid is associated with protection against bone loss